425: Aerovate Therapeutics to Merge with Jade Biosciences in $300 Million Deal Focused on Autoimmune Therapies

Aerovate Therapeutics and Jade Biosciences announced a merger agreement, with Jade receiving a $300 million private investment to advance its autoimmune disease pipeline.

Summary

• Aerovate Therapeutics and Jade Biosciences have entered into a merger agreement.
• Jade Biosciences will receive approximately $300 million in gross proceeds through a private investment, including the conversion of $95 million in convertible notes.
• The funding is expected to support operations through 2027.
• Pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders are expected to own approximately 98.4%.
• Aerovate expects to distribute a dividend of approximately $65 million to its pre-merger stockholders.
• The merger is expected to close in the first half of 2025.
• The combined company will operate under the name Jade Biosciences and trade on Nasdaq under the ticker symbol JBIO.
• Jade's lead program, JADE-001, targets Immunoglobulin A nephropathy (IgAN), which affects approximately 169,000 patients in the United States, several hundred thousand in Europe, and over a million patients in Asia.
• The U.S. total addressable market for IgAN is expected to surpass $10 billion.
• JADE-001 is expected to enter clinical trials in the second half of 2025, with initial results expected in the first half of 2026.
• Jade also has two other undisclosed antibody programs, JADE-002 and JADE-003, in preclinical development targeting systemic autoimmune diseases.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the merger, substantial funding, and promising pipeline. The focus on a large unmet need in IgAN and the potential for best-in-class therapies contribute to the positive sentiment.

Positives

• Jade Biosciences is receiving substantial funding ($300 million) to advance its pipeline of autoimmune disease therapies.
• The merger provides Jade Biosciences with access to public markets via Aerovate's Nasdaq listing.
• Jade's lead program, JADE-001, targets a significant unmet need in IgAN, with a large potential market.
• JADE-001 has the potential to be a best-in-class anti-APRIL monoclonal antibody with an extended dosing interval.
• The company has a strong team of experienced drug developers and company builders.
• Aerovate expects to distribute a dividend of approximately $65 million to its pre-merger stockholders shortly prior to closing.

Negatives

• Pre-merger Aerovate stockholders will own a small percentage (approximately 1.6%) of the combined company.
• The merger is subject to customary closing conditions, including regulatory and stockholder approvals, which could delay or prevent the transaction.
• The success of JADE-001 and other pipeline programs is subject to clinical trial risks and regulatory approvals.
• The company is still in early stages of clinical development, with JADE-001 expected to enter clinical trials in the second half of 2025.

Risks

• The merger may not be completed if the conditions to closing are not satisfied.
• Clinical trials for JADE-001 and other programs may not be successful.
• Regulatory approvals for Jade's therapies may not be obtained.
• The company may face competition from other companies developing therapies for autoimmune diseases.
• The company's cash resources may not be sufficient to fund operations through 2027 if development plans change or costs increase.
• The company's estimates of the IgAN market size may not be accurate.

Future Outlook

The combined company, Jade Biosciences, is expected to advance its pipeline of therapies focused on autoimmune diseases, with JADE-001 on track to enter the clinic in the second half of 2025 and two additional pre-clinical programs advancing steadily.

Management Comments

• Tom Frohlich, CEO of Jade Biosciences, stated that the merger will enable Jade to rapidly advance its portfolio of therapies focused on autoimmune diseases.
• Andrew King, Chief Scientific Officer of Jade Biosciences, is excited about the potential of JADE-001 to provide disease-modifying impact to patients with IgAN.

Industry Context

The merger reflects a growing interest in developing novel therapies for autoimmune diseases, particularly IgAN, which has a significant unmet medical need and a large market opportunity. The focus on APRIL inhibition aligns with current trends in IgAN treatment development.

Comparison to Industry Standards

• The document mentions sibeprenlimab, an anti-APRIL monoclonal antibody currently in Phase 3 development, as a comparator for JADE-001.
• The document references TACI-Fc fusion proteins that inhibit both APRIL and BAFF, such as atacicept, as existing approaches to targeting the plasma cell compartment in IgAN.
• The document notes that JADE-001 aims to combine superior potency with extended pharmacokinetic exposures, potentially surpassing the clinical activity of existing anti-APRIL mAbs.

Stakeholder Impact

• Shareholders of Aerovate will receive a dividend of approximately $65 million.
• Patients with IgAN may benefit from the development of new, disease-modifying therapies.
• Investors in Jade Biosciences are expected to see a return on their investment if the company's pipeline is successful.
• Employees of both companies may be affected by the merger, but the document does not provide specific details.

Next Steps

• Obtain stockholder approval for the merger.
• Secure regulatory approvals for the merger.
• Close the merger transaction in the first half of 2025.
• Initiate healthy volunteer trial with JADE-001 in the second half of 2025.
• Disclose initial results from the JADE-001 Human Volunteer study in the first half of 2026.
• Advance JADE-002 and JADE-003 into clinical development.

Key Dates